Bioventus Inc.

BVS

$14.22

-0.97%

2026-09-04 10:30:14 EDT-$0.14

Healthcare

Medical - Devices

NASDAQ

Active Trading

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s ...

Price Action of BVS

$14.22

-0.97%-$0.14

High—

Low—

52W High-10.5%

Rel. vol—

Interval

Range60m

Volume—SMA5SMA10

—

Bioventus Inc. is a global medical device company headquartered in Durham, North Carolina, founded in 2012. The company focuses on relieving pain and addressing musculoskeletal therapies, offering a comprehensive portfolio of products for active healing and surgical orthobiologics. Key products include pain treatments such as intra-articular hyaluronic acid injections (Durolane, ...Bioventus Inc. is a global medical device company headquartered in Durham, North Carolina, founded in 2012. The company focuses on relieving pain and addressing musculoskeletal therapies, offering a comprehensive portfolio of products for active healing and surgical orthobiologics. Key products include pain treatments such as intra-articular hyaluronic acid injections (Durolane, GELSYN-3, SUPARTZ), peripheral nerve stimulation (Stimrouter, TalisMann), and the XCELL PRP System. In surgical solutions, Bioventus provides precision bone resection tools, ultrasonic surgical systems (neXus, BoneScalpel), and bone graft substitutes (Osteoamp, Signafuse, Purebone, Reficio). Additionally, it offers restorative therapies like minimally invasive fracture treatments and the Exogen ultrasound bone stimulation system. The company generates revenue through sales to healthcare institutions, physicians, and distributors. Financially, Bioventus reported a market cap of approximately $957 million, with a gross profit margin of 68% and a net profit margin of 9.4%. The company employs about 1,105 people worldwide. Leadership is headed by CEO Robert Claypoole, with key executives including Mark Singleton, Katrina Church, and others. Bioventus went public in February 2021 on NASDAQ under the ticker BVS.ExpandCollapse

Founded

2012

Employees

950

CEO

Robert Claypoole

Full Name

Bioventus Inc.

Sector

Healthcare

Industry

Medical - Devices

ROE

28.39%

Market Cap

$0.97B

Current Ratio

1.69

WACC

7.58%

ROIC

20.08%

Contact Information

http://www.bioventus.com

919 474 6700

4721 Emperor Boulevard, Durham, NC 27703

Key Metrics of BVS

Snapshot

Latest / TTM · 6 periods

Market Cap

$971.30M

ROCE

11.9%

EV / EBITDA

12.90x

+0.7% YoY

FCF Yield

9.8%

-4.6% YoY

Cash Conversion Cycle

203.7d

Current Ratio

1.69

Quick take

TTM —

Positive CCC

Financial Highlights of BVS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

68.0%

Net Margin

9.4%

P/E Ratio

17.69x

n/a

Debt / Equity

1.16

n/a

Current Ratio

1.69

Dividend Yield

0.0%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of BVS

Upcoming

Sep 27, 2026In 23 days
Q3 FY2026 · Estimated results
Est. EPS $0.16 · Revenue $149.51M · 3 analysts
Dec 27, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.25 · Revenue $169.97M · 3 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.78 · Revenue $604.78M · 4 analysts
Mar 27, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.15 · Revenue $140.35M · 1 analysts

Recent history

Aug 5, 2026
Q2 FY2026 · Results reported
EPS $0.47 · Revenue $153.21M
View filing
May 6, 2026
Q1 FY2026 · Results reported
EPS $0.04 · Revenue $132.09M
View filing
Mar 5, 2026
FY2025 · Annual results
EPS $0.33 · Revenue $568.09M
View filing
Nov 4, 2025
Q3 FY2025 · Results reported
EPS $0.05 · Revenue $138.65M
View filing
Aug 6, 2025
Q2 FY2025 · Results reported
EPS $0.11 · Revenue $147.66M
View filing
May 6, 2025
Q1 FY2025 · Results reported
EPS $-0.04 · Revenue $123.88M
View filing

Financial Statements of BVS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$568.1M	-0.9%	+16.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$22.7M	+167.8%	+974.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+67.3%	-0.6%	+1.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+10.3%	+593.2%	+85.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+4.0%	+168.4%	+826.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$71.4M	+89.0%	+126.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+12.6%	+90.7%	+95.0%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	169.1%	-25.5%	-19.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.70x	+29.9%	+0.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$683.6M	-6.1%	+3.5%

Actual vs Estimate

A Dec 31Q Sep 27

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	0.33 vs 0.66	-50.1%	0.47 vs 0.16	+194.4%
Revenue Surprise	$568.1M vs $565.9M	+0.4%	$153.2M vs $149.5M	+2.5%

Insider Transactions of BVS

Acquisitions (A)

Since Jun 3, 2026

Disposals (D)

Since Jun 3, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 3, 2026	Bartholdson John A.	director, 10 percent owner:	Restricted Stock Units	A	25,146	—
Jun 3, 2026	SUTTER MARTIN P	director, 10 percent owner:	Restricted Stock Units	A	25,146	—
Jun 3, 2026	STALNECKER SUSAN M	director	Restricted Stock Units	A	25,146	—
Jun 3, 2026	NOHRA GUY P	director	Restricted Stock Units	A	25,146	—
Jun 3, 2026	NEELS GUIDO J	director	Restricted Stock Units	A	25,146	—

Earnings Call Transcript of BVS

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Bioventus Inc. Second Quarter 2026 Earnings Conference Call. [Operator Instructions] I'd now like to hand today's conference over to Dave Crawford. Please go ahead. David Crawford: Thanks, Regina, and good morning, everyone, and thanks for joining us. It is my pleasure to welcome you to the Bioventus 2026 Second Quarter Earnings Conference Call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO. Rob will provide an update on our 2026 priorities and the second quarter highlights, and then Mark will review second quarter results and discuss our 2026 financial guidance. We will finish the call with Q&A. A presentation for today's call is available on the Investors section of our website, bioventus.com. Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the SEC, including Item 1A Risk Factors in the company's Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in the company's filings made with the SEC. You are cautioned not to place undue reliance upon any forward-looking statements, which may speak only as of the date made. Although the company may voluntarily do so from time to time, it undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. This call will also include references to certain financial measures that are not calculated in accordance with U.S. generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP or adjusted financial measures. Important disclosures about the definitions and reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investors section of our website at bioventus.com. And now, I'll turn the call over to Rob. Robert Claypoole: Thank you, Dave. Good morning, everyone, and thanks for joining our call today. Bioventus continued its positive momentum in the second quarter, delivering solid financial results across our business. As we continue to strengthen our commercial, operational and financial fundamentals, we are seeing encouraging leading indicators that reinforce our confidence in our future growth drivers. As such, we are reiterating our full year guidance on all metrics and are confident that our long-range growth prospects will drive enhanced value for …

Leadership Team of BVS

8 executives

Name	Title	Compensation	Gender	Year Born	Status
Robert Claypoole	President, Chief Executive Officer & Director	USD 1,653,629	Male	1972	Active
Mark Singleton	Senior Vice President & Chief Financial Officer	USD 833,819	Male	1969	Active
Anthony D'Adamio	Senior Vice President, General Counsel & Corporate Secretary	USD 713,659	Male	1961	Active
Helen Leupold	Senior Vice President & Chief Human Resources Officer	—	Female	—	Active
Katrina J. Church	Senior Vice President & Chief Compliance Officer	—	Female	1962	Active
Dave Venner	Senior Vice President & GM of Surgical	—	Male	—	Active
David Crawford	Vice President of Investor Relations & Treasurer	—	Male	—	Active
Mike Crowe	Senior Vice President of Operations	—	Male	—	Active

Recent News of BVS

Zacks Investment Research8/24/2026Neutral

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Zacks Investment Research8/20/2026Neutral

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Zacks Investment Research8/7/2026Neutral

Is Bioventus (BVS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Seeking Alpha8/5/2026Neutral

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

MarketBeat8/5/2026Neutral

Bioventus Q2 Earnings Call Highlights

Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.

Historical Employee Count of BVS

Current

930

Change

+0.00%

Minimum

930

Maximum

1,200

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	930	10-K	Mar 5, 2026	View
Dec 31, 2024	930	10-K	Mar 11, 2025	View
Dec 31, 2023	970	10-K	Mar 12, 2024	View
Dec 31, 2022	1,120	10-K	Mar 31, 2023	View
Dec 31, 2021	1,200	10-K	Mar 11, 2022	View

Related stocksMedical - Devices

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Bioventus Inc.